Intrathecal AAV9/AP4M1 gene therapy for hereditary spastic paraplegia 50 shows safety and efficacy in preclinical studies is a research paper published in Journal of Clinical Investigation (2023). On theSindex it has a DataRank of 0.571. It has been cited 44 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.571
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →CureSPG50 Foundation
Grant: CureSPG50 Foundation to SJG
NICHD NIH HHS
Grant: P50 HD105351
Intramural NIH HHS
Grant: Z01 HD001607
Intramural NIH HHS
Grant: ZIA HD001607
Wellcome Trust
Grant: unidentified
unidentified
National Institutes of Health
Grant: 1ZIAHD001607-31
Protein Trafficking In The Endosomal-Lysosomal System
FWCI
5.01
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Sbno1 mediates cell–cell communication between neural stem cells and microglia through small extracellular vesicles
Additional file 1 of Sbno1 mediates cell–cell communication between neural stem cells and microglia through small extracellular vesicles